THOXF 0.34 BioPorto A/S
| Range: | 0.212-0.43451 | Vol Avg: | 806 | Last Div: | 0 | Changes: | -0.46 |
| Beta: | 1.25 | Cap: | 0.12B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Fri Dec 13 2019 | Empoloyees: | 29 | ||
| CUSIP: | CIK: | ISIN: | DK0011048619 | Country: | DK | ||
| CEO: | Mr. Peter Moerch Eriksen B.B.A., BBA | Website: | https://bioporto.com | ||||
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow